This is a preview of subscription content, log in via an institution to check access.
Rights and permissions
About this article
Cite this article
Basiliximab confers significant clinical benefit for marginal cost. Pharmacoecon. Outcomes News 399, 5 (2003). https://doi.org/10.1007/BF03275832
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03275832